COEPTIS Launches COEP Venture Group to Invest in AI and Automation Startups

COEPTIS Expands into AI Investment with COEP Venture Group

COEPTIS, Inc. (NASDAQ: COEP), a company known for its work in biotechnology and therapeutic solutions, has announced a significant expansion into the realm of artificial intelligence and automation. The company has launched COEP Venture Group, a new investment arm dedicated to funding and accelerating technology startups specializing in Artificial Intelligence (AI), Robotic Process Automation (RPA), and AI Agents 1

1

2

Strategic Focus and Investment Areas

COEP Venture Group aims to identify and support high-potential startups that are shaping the future of automation, intelligent systems, and AI-driven enterprise solutions. The investment focus includes:

1. Artificial Intelligence (AI): Advanced machine learning models, predictive analytics, and AI-driven enterprise solutions.
2. Robotic Process Automation (RPA): AI-powered automation to streamline workflows and enhance business operations.
3. AI Agents & Intelligent Systems: Autonomous AI-powered assistants and decision-making frameworks.
4. Emerging Technologies: Strategic investments in blockchain applications, data analytics platforms, and next-generation enterprise software 1

   1

   .

Leadership and Expertise

The venture group will benefit from the expertise of Michael Woloshin, a seasoned entrepreneur with extensive experience in technology, AI, and marketing automation. Woloshin, co-founder of Recruiter.com and founder of NexGenAI Solutions Group, will play a crucial role in driving COEP Venture Group's mission to foster innovation and expand market opportunities for emerging technology companies 1

1

2

Synergies with Existing Operations

COEP Venture Group will leverage NexGenAI Solutions Group, which powers COEPTIS's latest acquisition, NexGenAI Affiliates Group, to provide marketing services to portfolio companies. This initiative ensures that startups receive not only funding but also strategic exposure and market positioning 1

1

2

Related Stories

Coeptis Therapeutics Acquires AI-Powered Marketing Platform, Launches New Tech Division

AI and Healthcare: Roche, Avant Technologies, and Ainnova Partner to Combat Diabetic Retinopathy

Healthcare AI Market Poised for Explosive Growth as New Technologies Emerge

AI Revolutionizes Healthcare: Avant Technologies and Roche Partner to Combat Diabetic Retinopathy

COEPTIS's Expanding Portfolio

While venturing into AI investments, COEPTIS maintains its focus on biopharmaceutical innovations. The company's therapeutic portfolio includes:

1. An allogeneic cellular immunotherapy platform and DVX201, licensed from Deverra Therapeutics.
2. A universal, multi-antigen CAR technology (SNAP-CAR) licensed from the University of Pittsburgh.
3. GEAR cell therapy and companion diagnostic platforms developed in collaboration with VyGen-Bio and researchers at the Karolinska Institute 1

   1

   2

   2

   .

Impact on Business Landscape

Dave Mehalick, CEO of Coeptis Therapeutics Holdings Inc., emphasized the transformative potential of AI-driven automation and intelligent agents in business operations. The launch of COEP Venture Group aligns with the company's vision of investing in disruptive technologies that redefine industries 1

1

2

As COEPTIS expands its reach into the AI and automation sectors, it positions itself at the intersection of biotechnology and advanced computing technologies, potentially creating synergies between these rapidly evolving fields.